Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Medicare D-lemmas

Ann Kepler  |  Issue: January 2007  |  January 1, 2007

Yet, some Part D plans require authorization for inexpensive drugs, such as prednisone. This confusion and inconsistency led Dr. Eisenberg to a straightforward view of the pre-approval process. “This is another layer of hassle with no purpose. Patients should get what they need with less hassle factor,” he says.

Alfred Denio, MD, a rheumatologist at the Center for Arthritis and Rheumatic Diseases in Norfolk, Va., agrees. “There is usually a good reason a doctor does not use a drug on a formulary list [and instead uses] one that is already working but not on the list,” he claims. “The reason is comorbidity.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Like most rheumatologists, Dr. Denio has patients who, because of their age, are being treated for several diseases that are often chronic. For example, a patient with RA, diabetes, asthma, heart disease, and high blood pressure needs a carefully balanced drug regimen for effective treatment and safety. The choice of medication for any one problem, therefore, may not be an easy decision—nor can it be a decision dictated by an insurance drug formulary.

Logistical Questions Remain

In addition, the prior authorization process itself causes logistics problems. A patient can appeal a drug denied by his or her plan and can also request a reconsideration (level 2) appeal on a denied Part D claim. This is the point at which the patient can appoint the physician to represent him or her in the claim, which requires a form signed by both the physician and the patient that is good for one year.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

One of the early complaints is that patients in rural areas, such as those in Dr. Morris’ Appalachian areas and Dr. Smith’s remote northern New Mexico regions, have to travel long distances to sign the authorization form. In addition, the staff in the physician’s office have to complete the paperwork and follow up throughout the process—either by mail, fax, or telephone.

This erosion of staff time has become a cost factor for many practices. Herb Baraf, MD, who works in one of the largest practices in the country in the suburbs of Washington, D.C., puts it succinctly, “The ability to get through the day is degraded terribly.”

In fact, Dr. Baraf considers this problem so important to some practices that they are forced to close down for a day a week to balance costs. “This is not our motto in our practice,” ensures Dr. Baraf, “but it can be a problem for many practitioners.”

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Billing/CodingPractice Support Tagged with:BillingCodingHealth InsuranceMedicarePractice ManagementReimbursementrheumatologist

Related Articles

    Generic-Drug Price Fixing: Is It Happening?

    May 17, 2018

    It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

    Georgia Bonney

    Prior Authorization Woes: Barriers to & Delays in Care, Administrative Hassles & Potential Solutions

    August 6, 2021

    As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.

    Dr. Christopher Morris: Rheumatologist, Bridge Player & Lifelong Magician

    January 17, 2019

    Ever wonder how magicians know what card you pulled out of the deck, make objects vanish or unlink and link solid metal rings? Christopher Morris, MD, knows how these tricks are performed, but he won’t tell you. A rheumatologist who has been in private practice for 25 years at Arthritis Associates, Kingsport, Tenn., he has…

    Rheum After 5: Dr. Christopher Morris, Jeopardy! Contestant

    September 11, 2023

    The clock was ticking. Christopher Morris, MD, then an intern and resident in internal medicine at the University of Tennessee (UT) Medical Center, Knoxville, had just 30 seconds to think of the correct response. He already had the answer. His challenge was coming up with the question. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEFinal Jeopardy In 1988,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences